Although diffuse large B-cell lymphoma(DLBCL)is considered as a curable disease after standard immunochemotherapy,approximately30%of patients would succumb to short survival.To date,clinical presentations and gene exp...Although diffuse large B-cell lymphoma(DLBCL)is considered as a curable disease after standard immunochemotherapy,approximately30%of patients would succumb to short survival.To date,clinical presentations and gene expressions have been used to identify these high-risk patients.展开更多
ABT-199(venetoclax)induces cell apoptosis in lymphoid malignancies mainly through the mitochondrial apoptosis pathway.However,long-term use of ABT-199 causes sec-ondary drug resistance,which limits its use.Here,we sho...ABT-199(venetoclax)induces cell apoptosis in lymphoid malignancies mainly through the mitochondrial apoptosis pathway.However,long-term use of ABT-199 causes sec-ondary drug resistance,which limits its use.Here,we show that the acquired resistance to ABT-199 in diffuse large B-cell lymphoma(DLBCL)cells is related to the upregulation of phosphorylated vascular endothelial growth factor re-ceptor 2(p-VEGFR2),BCL-XL and MCL-1.展开更多
基金This work was supported by Zhejiang Provincial Natural Science Foundation of China(No.LY19H080009,and LY20H080008)Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province(China)(No.JBZX-201904)+1 种基金This study is also supported by the major projects of Zhejiang Provincial Department of Science and Technology 491010+J3210NZJ(China)the Research Project of Jinan Microecological Biomedicine Shandong Laboratory,Jinan,China.
文摘Although diffuse large B-cell lymphoma(DLBCL)is considered as a curable disease after standard immunochemotherapy,approximately30%of patients would succumb to short survival.To date,clinical presentations and gene expressions have been used to identify these high-risk patients.
基金supported in part by the research plan of the National Natural Science Foundation of China(No.81372256)。
文摘ABT-199(venetoclax)induces cell apoptosis in lymphoid malignancies mainly through the mitochondrial apoptosis pathway.However,long-term use of ABT-199 causes sec-ondary drug resistance,which limits its use.Here,we show that the acquired resistance to ABT-199 in diffuse large B-cell lymphoma(DLBCL)cells is related to the upregulation of phosphorylated vascular endothelial growth factor re-ceptor 2(p-VEGFR2),BCL-XL and MCL-1.
